It was a pleasure to talk to Stephen Hanauer (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around his presentation on ‘EMERGING IBD THERAPIES’ which was presented at the virtual 2021 Crohn’s & Colitis Congress.
- Could you give us a brief overview of the current treatment options for patients with moderate‑to‑severe ulcerative colitis and Crohn’s disease? (0:18)
- What are the current unmet needs in the treatment of patients who have had an inadequate response to prior treatment with TNF inhibitors? (1:55)
- How do you expect the use of IL‑12/23 inhibitors to develop in the coming years? (3:01)
- What are the potential advantages of oral JAK inhibitors and S1P agents, and what is the current status of their development? (3:54)
- What remaining issues need to be addressed in the treatment of patients with moderate‑to‑severe ulcerative colitis and Crohn’s disease? (5:38)
Disclosures: Stephen Hanauer has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Marc Ferratnte, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Marc Ferrante, UEG 2021: Risankizumab as a Maintenance Therapy for Crohn’s Disease
Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) kindly took the time to speak with touchIMMUNOLOGY about the 52-week results from the phase 3 FORTIFY study investigating the efficacy and safety of risankizumab as a maintenance treatment in patients with Crohn’s disease. His presentation entitled ‘EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS […]
Marc Ferrante, UEG 2021: Unmet Needs in Managing Crohn’s Disease
It was a pleasure to discuss with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) the current unmet needs in the treatment of patients with Crohn’s disease. Disclosures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!